198 related articles for article (PubMed ID: 23435671)
1. KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer.
Boeck S; Jung A; Laubender RP; Neumann J; Egg R; Goritschan C; Ormanns S; Haas M; Modest DP; Kirchner T; Heinemann V
J Gastroenterol; 2013 Apr; 48(4):544-8. PubMed ID: 23435671
[TBL] [Abstract][Full Text] [Related]
2. EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104.
Boeck S; Jung A; Laubender RP; Neumann J; Egg R; Goritschan C; Vehling-Kaiser U; Winkelmann C; Fischer von Weikersthal L; Clemens MR; Gauler TC; Märten A; Klein S; Kojouharoff G; Barner M; Geissler M; Greten TF; Mansmann U; Kirchner T; Heinemann V
Br J Cancer; 2013 Feb; 108(2):469-76. PubMed ID: 23169292
[TBL] [Abstract][Full Text] [Related]
3. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
[TBL] [Abstract][Full Text] [Related]
4. Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3.
da Cunha Santos G; Dhani N; Tu D; Chin K; Ludkovski O; Kamel-Reid S; Squire J; Parulekar W; Moore MJ; Tsao MS
Cancer; 2010 Dec; 116(24):5599-607. PubMed ID: 20824720
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104).
Heinemann V; Vehling-Kaiser U; Waldschmidt D; Kettner E; Märten A; Winkelmann C; Klein S; Kojouharoff G; Gauler TC; von Weikersthal LF; Clemens MR; Geissler M; Greten TF; Hegewisch-Becker S; Rubanov O; Baake G; Höhler T; Ko YD; Jung A; Neugebauer S; Boeck S
Gut; 2013 May; 62(5):751-9. PubMed ID: 22773551
[TBL] [Abstract][Full Text] [Related]
6. Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer.
Haas M; Ormanns S; Baechmann S; Remold A; Kruger S; Westphalen CB; Siveke JT; Wenzel P; Schlitter AM; Esposito I; Quietzsch D; Clemens MR; Kettner E; Laubender RP; Jung A; Kirchner T; Boeck S; Heinemann V
Br J Cancer; 2017 May; 116(11):1462-1469. PubMed ID: 28449008
[TBL] [Abstract][Full Text] [Related]
7. Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody.
Ormanns S; Heinemann V; Raponi M; Isaacson J; Laubender RP; Haas M; Kruger S; Kleespies A; Mann E; Bartosiewicz M; Kirchner T; Boeck S
Eur J Cancer; 2014 Jul; 50(11):1891-9. PubMed ID: 24857044
[TBL] [Abstract][Full Text] [Related]
8. Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial.
Wang JP; Wu CY; Yeh YC; Shyr YM; Wu YY; Kuo CY; Hung YP; Chen MH; Lee WP; Luo JC; Chao Y; Li CP
Oncotarget; 2015 Jul; 6(20):18162-73. PubMed ID: 26046796
[TBL] [Abstract][Full Text] [Related]
9. A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research.
Oh DY; Lee KW; Lee KH; Sohn CH; Park YS; Zang DY; Ryoo HM; Song HS; Kim JS; Kang HJ; Kim BS; Bang YJ
Invest New Drugs; 2012 Jun; 30(3):1164-74. PubMed ID: 21404106
[TBL] [Abstract][Full Text] [Related]
10. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.
D'Angelo SP; Janjigian YY; Ahye N; Riely GJ; Chaft JE; Sima CS; Shen R; Zheng J; Dycoco J; Kris MG; Zakowski MF; Ladanyi M; Rusch V; Azzoli CG
J Thorac Oncol; 2012 Dec; 7(12):1815-1822. PubMed ID: 23154553
[TBL] [Abstract][Full Text] [Related]
11. EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer.
Mack PC; Holland WS; Burich RA; Sangha R; Solis LJ; Li Y; Beckett LA; Lara PN; Davies AM; Gandara DR
J Thorac Oncol; 2009 Dec; 4(12):1466-72. PubMed ID: 19884861
[TBL] [Abstract][Full Text] [Related]
12. Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models.
Dragnev KH; Ma T; Cyrus J; Galimberti F; Memoli V; Busch AM; Tsongalis GJ; Seltzer M; Johnstone D; Erkmen CP; Nugent W; Rigas JR; Liu X; Freemantle SJ; Kurie JM; Waxman S; Dmitrovsky E
Cancer Prev Res (Phila); 2011 Jun; 4(6):818-28. PubMed ID: 21636548
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
Oncologist; 2012; 17(1):13. PubMed ID: 22210086
[TBL] [Abstract][Full Text] [Related]
14. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.
Zhu CQ; da Cunha Santos G; Ding K; Sakurada A; Cutz JC; Liu N; Zhang T; Marrano P; Whitehead M; Squire JA; Kamel-Reid S; Seymour L; Shepherd FA; Tsao MS;
J Clin Oncol; 2008 Sep; 26(26):4268-75. PubMed ID: 18626007
[TBL] [Abstract][Full Text] [Related]
15. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.
Jackman DM; Miller VA; Cioffredi LA; Yeap BY; Jänne PA; Riely GJ; Ruiz MG; Giaccone G; Sequist LV; Johnson BE
Clin Cancer Res; 2009 Aug; 15(16):5267-73. PubMed ID: 19671843
[TBL] [Abstract][Full Text] [Related]
16. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
17. Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.
Rulli E; Marabese M; Torri V; Farina G; Veronese S; Bettini A; Longo F; Moscetti L; Ganzinelli M; Lauricella C; Copreni E; Labianca R; Martelli O; Marsoni S; Broggini M; Garassino MC;
Ann Oncol; 2015 Oct; 26(10):2079-84. PubMed ID: 26209642
[TBL] [Abstract][Full Text] [Related]
18. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.
Richman SD; Seymour MT; Chambers P; Elliott F; Daly CL; Meade AM; Taylor G; Barrett JH; Quirke P
J Clin Oncol; 2009 Dec; 27(35):5931-7. PubMed ID: 19884549
[TBL] [Abstract][Full Text] [Related]
19. Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.
Diep CH; Munoz RM; Choudhary A; Von Hoff DD; Han H
Clin Cancer Res; 2011 May; 17(9):2744-56. PubMed ID: 21385921
[TBL] [Abstract][Full Text] [Related]
20. Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503.
Amann JM; Lee JW; Roder H; Brahmer J; Gonzalez A; Schiller JH; Carbone DP
J Thorac Oncol; 2010 Feb; 5(2):169-78. PubMed ID: 20035238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
